FDA Announces Temporary Enforcement Discretion for Clozapine REMS Requirements
FDA is temporarily exercising additional enforcement discretion with respect to certain Clozapine REMS program requirements to ensure continuity of care for patients taking clozapine recently discharged from an inpatient setting. For details, see here.
USP Publishes Final Compounding Chapters <795> and <797>
USP has published the final versions of compounding chapters <795> and <797> in the USP-NF 2023, Issue 1. For FAQs and fact sheets on the chapters, see here.
Physician Fee Schedule Updates Vaccine Administration Payment for 2023
CMS issued the final physician fee schedule for CY 2023, which updates vaccine payment information. The CY 2023 payment amount for influenza, pneumococcal, and HBV vaccine administration is $31.14. This amount will be geographically adjusted based upon the fee schedule area where the preventive vaccine is administered. With regard to COVID-19 vaccine administration, for CY 2023 the payment amount is $41.52. This differential will remain in place until the end of the calendar year in which the current Emergency Use Authorization declaration for drugs and biologicals with respect to COVID-19 ends. Thereafter, the payment amount for COVID-19 vaccine administration will be adjusted to align with the payment rate for the other Medicare Part B preventive vaccines.
CMS will also continue the in-home additional payment for the administration of COVID-19 vaccines. For CY 2023 the in-home additional payment amount for COVID-19 vaccine administration described by HCPCS code M0201 is $36.85, and payment for these services will be adjusted for geographic cost differences.
For CMS’ fact sheet, click here. For CMS’ press release, click here. For the final rule, click here.
|